CHEMMC Stock Overview
Engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
ChemoMetec A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr.379.80 |
| 52 Week High | kr.527.75 |
| 52 Week Low | kr.324.00 |
| Beta | 1.26 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -13.13% |
| 3 Year Change | -44.39% |
| 5 Year Change | 134.16% |
| Change since IPO | 2,501.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| CHEMMC | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 0% | 0.2% | 0.4% |
| 1Y | -13.1% | -40.3% | 6.2% |
Return vs Industry: CHEMMC exceeded the UK Life Sciences industry which returned -39.9% over the past year.
Return vs Market: CHEMMC underperformed the UK Market which returned 6.4% over the past year.
Price Volatility
| CHEMMC volatility | |
|---|---|
| CHEMMC Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 7.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: CHEMMC's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine CHEMMC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 171 | Martin Behrens | chemometec.com |
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in are areas of cell-based therapy, cancer, and stem cell research, development, and manufacturing of pharmaceuticals as well as production and quality control of animal semen and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal reproduction; NucleoCounter SCC-100, a somatic cell counter used to measure the number of somatic cells in a milk sample; and NucleoCounter YC-100, an automated yeast cell counter used to measure the total cell count and viability of yeast cells in suspension.
ChemoMetec A/S Fundamentals Summary
| CHEMMC fundamental statistics | |
|---|---|
| Market cap | kr.6.28b |
| Earnings (TTM) | kr.143.80m |
| Revenue (TTM) | kr.401.54m |
43.6x
P/E Ratio15.6x
P/S RatioIs CHEMMC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CHEMMC income statement (TTM) | |
|---|---|
| Revenue | kr.401.54m |
| Cost of Revenue | kr.47.43m |
| Gross Profit | kr.354.11m |
| Other Expenses | kr.210.31m |
| Earnings | kr.143.80m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 11, 2024
| Earnings per share (EPS) | 8.26 |
| Gross Margin | 88.19% |
| Net Profit Margin | 35.81% |
| Debt/Equity Ratio | 0.2% |
How did CHEMMC perform over the long term?
See historical performance and comparison